CG Oncology vs HCW Biologics
CG Oncology is the larger business, with $4.0m of revenue in fiscal 2025 against $54,232 for HCW Biologics (74.5 times as much). CG Oncology grew faster (254.7% against -97.9%). CG Oncology kept more of each dollar of sales as profit: a net margin of -3985.0% against -14677.1%. CG Oncology carries less debt relative to equity (0.4% against 246.3%).
| Latest fiscal year | CG OncologyCGON, 2025 | HCW BiologicsHCWB, 2025 |
|---|---|---|
| Revenue | $4.0m | $54,232 |
| Revenue growth | 254.7% | -97.9% |
| Net income | −$161m | −$8.0m |
| Operating margin | -4722.1% | -24270.7% |
| Net margin | -3985.0% | -14677.1% |
| Return on equity | -21.7% | — |
| Free cash flow | −$132m | −$13.4m |
| Cash | $32.5m | $2.0m |
| Total debt | $3.0m | $6.8m |
| Debt to equity | 0.4% | 246.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 142 | 35 |
| Market value | $5.69bn | $1.5m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 1 buys, 17 sales | 6 buys, 0 sales |